Saturday, September 23, 2023
Saturday, September 23, 2023

Canon Medical Systems USA Presents Its First-Ever U.S. Mobile Truck Tour with the Launch of Canon Across America

Canon Medical Systems USA, Inc. (CMSU), a global leader in innovative diagnostic imaging technology, is proud to announce its first-ever U.S. mobile tour, Canon Across America, March 24th through December 2, 2022.

Canon Medical Systems USA will bring its state-of-the-art AI medical devices to hospitals and local healthcare providers in a unique hands-on experience to create stronger community engagement throughout the year.

CMSU’s 50-city mobile tour kicks off in its Tustin, CA headquarters and will travel across the country. The Canon Across America mobile truck tour aims to provide healthcare professionals and hospitals across the U.S. the opportunity to connect with Canon’s innovative solution-focused portfolios at a hands-on level by providing a holistic 360-degree view of their solutions. In addition, Canon will provide live demos, supportive conversations with Canon’s industry experts, and an opportunity to experience the benefits Canon’s platforms offer at their convenience.

“Providing in-person experiences with current and new customers is key for us as a company. It’s a vital opportunity to connect, ask pressing questions in a face-to-face setting, and to learn more about better servicing their needs,” said David Hashimoto, Vice President of Marketing and Sales Strategy. “We’re allowing unprecedented access to our technologies to better guide healthcare professionals with the essential information needed to make important decisions about their patients and business.”

Yuji Hamada, President and CEO of Canon Medical Systems USA, agrees. “Canon’s 50-city tour is a unique opportunity for healthcare professionals to gain access to personalized demos. The next generation of medical imaging allows us to provide our customers flexible visits with Canon’s reps and to focus on key areas of interest important to them. We look forward to this year-long journey of meeting our customers, friends, and colleagues and showcasing the very best that Canon has to offer.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase...

The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to chemotherapy. An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis. The safety results of the combination are consistent with those of enfortumab vedotin in combination with pembrolizumab previously reported in cisplatin-ineligible patients with la/mUC.

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

"Dosing the first patient, on time, is a testament to our commitment to the clinical development of DA-1241 in patients with NASH," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "Based on the pre-clinical and clinical evidence generated to date, DA-1241 has demonstrated reduced hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control, and was shown to be well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). Given this data, we believe that the mechanism of action of this promising cardiometabolic asset will translate into a safe and effective treatment for NASH, a disease with no current treatment options. The two-part design of this trial provides optionality for a potential interim analysis in the first half of 2024 and we expect to report the full data in the second half of 2024."

Medmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech

The "U.S. Market Gateway Accelerator for BioSciences and MedTech", sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.S. with the opportunity to enter and grow their business in the U.S. market.

Karger Publishers New Journal – Immune System

“Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann."

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Robert Barrow, Chief Executive Officer and Director of MindMed. “Thanks in large part to the enthusiasm we have seen regarding MM-120 among investigators and patients, as well as the strong execution of our team, we were able to enroll almost 200 participants in this trial in just over a year. We anticipate sharing topline results during the fourth quarter of this year.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy